Beyond these primary endpoints, TRIUMPH-1 includes a range of secondary and exploratory endpoints that paint a fuller picture of retatrutide's clinical impact: Proportion of participants achieving 10%, 15%, and 20% or greater weight loss Changes in waist circumference Changes in cardiometabolic risk factors, including blood pressure, triglycerides, HDL cholesterol, LDL cholesterol, and fasting glucose Changes in HbA1c (a measure of average blood sugar over the preceding two to three months) Changes in liver enzymes and markers of hepatic health Patient-reported outcomes related to quality of life and physical function Safety and tolerability, including the incidence and severity of adverse events The secondary endpoints are particularly important for retatrutide because the Phase 2 data showed striking improvements across metabolic markers
Start your intake Can You Donate Plasma While Taking Tirzepatide
For detoxification: Weekly or biweekly sessions Flushing or warmth during the infusion These effects are temporary and typically resolve within a few minutes
Unregulated Injectable Products A major concern outside controlled laboratory settings is that injectable peptides like GHK-Cu are not approved as medicines by regulatory authorities such as the FDA or the EMA
Enteral nutrition (EN): Via nasogastric tube (NGT, short-term) or PEG/G-tube (long-term, Z93.1) when oral intake is insufficient or unsafe
doi: 10.1101/2023.06.22.546093v1
